HC Wainwright Lowers Carisma Therapeutics (NASDAQ:CARM) Price Target to $8.00

Carisma Therapeutics (NASDAQ:CARM) had its price target decreased by stock analysts at HC Wainwright from $9.00 to $8.00 in a research note issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective points to a potential upside of 429.80% from the stock’s previous close.

Separately, BTIG Research assumed coverage on Carisma Therapeutics in a research report on Thursday, April 11th. They set a “buy” rating and a $6.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Carisma Therapeutics has an average rating of “Buy” and a consensus target price of $8.60.

Carisma Therapeutics Stock Down 2.6 %

Shares of Carisma Therapeutics stock opened at $1.51 on Friday. The company has a quick ratio of 5.06, a current ratio of 5.06 and a debt-to-equity ratio of 0.01. Carisma Therapeutics has a 52-week low of $1.47 and a 52-week high of $9.77. The company has a market capitalization of $62.73 million, a P/E ratio of -0.44 and a beta of 1.00. The company has a 50 day moving average of $2.04 and a 200 day moving average of $2.39.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings data on Monday, April 1st. The company reported ($0.52) earnings per share for the quarter. The firm had revenue of $4.29 million during the quarter, compared to analyst estimates of $4.00 million. Carisma Therapeutics had a negative net margin of 582.34% and a negative return on equity of 154.04%. As a group, research analysts forecast that Carisma Therapeutics will post -1.65 EPS for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Carisma Therapeutics stock. SG Americas Securities LLC acquired a new stake in Carisma Therapeutics, Inc. (NASDAQ:CARM) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 13,653 shares of the company’s stock, valued at approximately $58,000. 44.27% of the stock is currently owned by hedge funds and other institutional investors.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.